Abstract
BackgroundThe small number of samples and the curse of dimensionality hamper the better application of deep learning techniques for disease classification. Additionally, the performance of clustering-based feature selection algorithms is still far from being satisfactory due to their limitation in using unsupervised learning methods. To enhance interpretability and overcome this problem, we developed a novel feature selection algorithm. In the meantime, complex genomic data brought great challenges for the identification of biomarkers and therapeutic targets. The current some feature selection methods have the problem of low sensitivity and specificity in this field.ResultsIn this article, we designed a multi-scale clustering-based feature selection algorithm named MCBFS which simultaneously performs feature selection and model learning for genomic data analysis. The experimental results demonstrated that MCBFS is robust and effective by comparing it with seven benchmark and six state-of-the-art supervised methods on eight data sets. The visualization results and the statistical test showed that MCBFS can capture the informative genes and improve the interpretability and visualization of tumor gene expression and single-cell sequencing data. Additionally, we developed a general framework named McbfsNW using gene expression data and protein interaction data to identify robust biomarkers and therapeutic targets for diagnosis and therapy of diseases. The framework incorporates the MCBFS algorithm, network recognition ensemble algorithm and feature selection wrapper. McbfsNW has been applied to the lung adenocarcinoma (LUAD) data sets. The preliminary results demonstrated that higher prediction results can be attained by identified biomarkers on the independent LUAD data set, and we also structured a drug-target network which may be good for LUAD therapy.ConclusionsThe proposed novel feature selection method is robust and effective for gene selection, classification, and visualization. The framework McbfsNW is practical and helpful for the identification of biomarkers and targets on genomic data. It is believed that the same methods and principles are extensible and applicable to other different kinds of data sets.
Highlights
The small number of samples and the curse of dimensionality hamper the better application of deep learning techniques for disease classification
Feng et al recently developed a new supervised discriminative sparse principal component analysis (PCA) (SDSPCA) method for multiview biological data, which has been applied to cancer classification and informative gene selection [2]
Two-class cancer data set DLBCL, multi-class cancer data set SRBCT and two single-cell data sets were visualized through the Multi-scale supervised clustering-based feature selection (MCBFS) method and principal component analysis (PCA) to demonstrate our method is effective and widely applicable
Summary
The small number of samples and the curse of dimensionality hamper the better application of deep learning techniques for disease classification. The current some feature selection methods have the problem of low sensitivity and specificity in this field Genomic data, such as gene expression data, have been widely utilized to explore the mechanisms underlying a series of disorders [1]. Only a small subset of genes is suitable for tumor classification To address these issues, some feature selection algorithms have recently been developed for identifying informative genes from genomic data of cancer [2,3,4,5]. Feng et al recently developed a new supervised discriminative sparse PCA (SDSPCA) method for multiview biological data, which has been applied to cancer classification and informative gene selection [2]. A neural network-based approach can be used to reduce the dimensions of single-cell RNA-seq data and predict cellular states and cell types [12]
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.